• All Categories
  • UK News
  • Europe
  • Global
  • R & D
  • Sales & Marketing
  • Manufacturing
  • Digital
  • Industry Insights
  • Appointments
  • Interviews
  • Features
  • Industry Facts
GSK’s RSV vaccine approved by MHRAGSK’s RSV vaccine approved by MHRA
GSK’s RSV vaccine approved by MHRA

GSK has announced that the MHRA has authorised its Arexvy respiratory syncytial virus (RSV) vaccine for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults over the age of 60.

Aug 24, 2023 R & D
PMEAPMEA
PMEA

Https://pmea.awardsplatform.com/

Aug 24, 2023
PharmaTimes COMMUNICATIONS AWARDSPharmaTimes COMMUNICATIONS AWARDS
PharmaTimes COMMUNICATIONS AWARDS

Pharmatimes.com/communications_awards

Aug 24, 2023
UKHSA opens new vaccine research centre in Wiltshire to prepare for future pandemicsUKHSA opens new vaccine research centre in Wiltshire to prepare for future pandemics
UKHSA opens new vaccine research centre in Wiltshire to prepare for future pandemics

Ministers have opened a new vaccine research centre at the UKHSA Porton Down campus in Wiltshire, intended to prepare for 'disease x', the next possible pandemic pathogen.

Aug 24, 2023 UK News
CommentComment
Comment

Research innovations in rare diseases and improving patient access

Aug 24, 2023
ContentsContents
Contents

Welcome to this issue of Pharmafocus!

Aug 24, 2023
PharmafocusPharmafocus
Pharmafocus

Pharmafocus.com

Aug 24, 2023
Merck’s ebola vaccine, Ervebo, approved by FDA for childrenMerck’s ebola vaccine, Ervebo, approved by FDA for children
Merck’s ebola vaccine, Ervebo, approved by FDA for children

On 3 August 2023, the FDA approved Merck’s Ervebo vaccine for children over 12 months.

Aug 24, 2023
Treatment programme for CVD to be developed as part of partnership between Novartis and IonisTreatment programme for CVD to be developed as part of partnership between Novartis and Ionis
Treatment programme for CVD to be developed as part of partnership between Novartis and Ionis

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and licence agreement with Novartis, aiming to discover, develop and commercialise a novel medicine for patients with lipoprotein(a) or lp(a)-driven cardiovascular disease (CVD).

Aug 24, 2023 Sales & Marketing
Contaminated cough syrup leads to WHO Medical Product AlertContaminated cough syrup leads to WHO Medical Product Alert
Contaminated cough syrup leads to WHO Medical Product Alert

The WHO has shared a medical product alert for an additional contaminated cough syrup medicine identified in Africa.

Aug 24, 2023 Global
RNAi treatment for hypertension developed by Alnylam and RocheRNAi treatment for hypertension developed by Alnylam and Roche
RNAi treatment for hypertension developed by Alnylam and Roche

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension in patients with high cardiovascular risk.

Aug 24, 2023 R & D
New open innovation hub opened by Astellas for tumour microenvironment researchNew open innovation hub opened by Astellas for tumour microenvironment research
New open innovation hub opened by Astellas for tumour microenvironment research

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended to open in October 2023.

Aug 24, 2023 Global